Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response.

BMC research notes - 4 Jun 2014

Boeckx Carolien, Weyn Christine, Vanden Bempt Isabelle, Deschoolmeester Vanessa, Wouters An, Specenier Pol, Van Laer Carl, Van den Weyngaert Danielle, Kockx Mark, Vermorken Jan B, Peeters Marc, Pauwels Patrick, Lardon Filip, Baay Marc

Abstract excerpt

BACKGROUND: Targeted therapy against the Epidermal Growth Factor Receptor (EGFR) is among the most promising molecular therapeutics for Head and Neck Squamous Cell Carcinoma (HNSCC). However, drug resistance limits the clinical efficacy of anti-EGFR monoclonal antibodies and no predictive biomarker has entered the clinic yet. METHODS: A retrospective clinical study was performed utilizing pathological specimens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alphapapillomavirus
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to DNA Primers

Share to ErbB Receptors

Share to Genes, ras

Share to Head and Neck Neoplasms

Share to Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 24899223
DOI: 10.1186/1756-0500-7-337
PMCID: PMC4067106

Genes

EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response.PMID 24899223Read ↗

Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).Semantic proximity Read ↗

EGFR Mutations in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods.Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.Semantic proximity Read ↗

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.Semantic proximity Read ↗

Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.Semantic proximity Read ↗

Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck.Semantic proximity Read ↗

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?Semantic proximity Read ↗

Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis.Semantic proximity Read ↗

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles.Semantic proximity Read ↗

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.Semantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.